Autologous stem cell-based therapy for sickle cell leg ulcer

A pilot study

José Válber L Meneses, Vitor Fortuna, Eliane Silva de Souza, Gildasio Cerqueira Daltro, Roberto Meyer, Caterina P. Minniti, Radovan Borojevic

Research output: Contribution to journalArticle

6 Citations (Scopus)

Abstract

Recurrent chronic leg ulcers are among the most severe vasculopathic complications of sickle cell disease (SCD). Their treatment remains a challenge. Stem cell therapy with bone marrow mononuclear cells (BMMC) is a promising new therapeutic option for other forms of chronic ulcers. This prospective pilot study was performed to evaluate safety and feasibility of BMMC implantation in patients with SCD and chronic leg ulcers (SCLU). Ulcer closure, recurrence and local pain were evaluated. BMMC were successfully administered to 23 SCLU patients and no serious adverse events occurred. During the 6-month follow-up period, 91·3% of patients had improved ulcer pain compared with baseline and 29·2% of the treated ulcers achieved total healing. The frequency of progenitor stem cells (CD34CD45low and fibroblast colony-forming units) in BMMC was found to be significantly reduced in SCLU patients and compared to SCD patients without ulcers (P < 0·004 and P < 0·01, respectively). No relationship was observed between treatment outcome and the number of implanted BM progenitor stem cells. In conclusion, BMMC implantation is a feasible and safe procedure, showing favourable outcomes for the treatment of SCLU, and encouraging further controlled clinical trials.

Original languageEnglish (US)
JournalBritish Journal of Haematology
DOIs
StateAccepted/In press - 2016

Fingerprint

Leg Ulcer
Cell- and Tissue-Based Therapy
Bone Marrow Cells
Stem Cells
Ulcer
Sickle Cell Anemia
Pain
Controlled Clinical Trials
Fibroblasts
Prospective Studies
Safety
Recurrence
Therapeutics

Keywords

  • Bone marrow
  • Clinical trial
  • Leg ulcer
  • Sickle cell disease
  • Stem cell transplantation

ASJC Scopus subject areas

  • Hematology

Cite this

Meneses, J. V. L., Fortuna, V., de Souza, E. S., Daltro, G. C., Meyer, R., Minniti, C. P., & Borojevic, R. (Accepted/In press). Autologous stem cell-based therapy for sickle cell leg ulcer: A pilot study. British Journal of Haematology. https://doi.org/10.1111/bjh.14326

Autologous stem cell-based therapy for sickle cell leg ulcer : A pilot study. / Meneses, José Válber L; Fortuna, Vitor; de Souza, Eliane Silva; Daltro, Gildasio Cerqueira; Meyer, Roberto; Minniti, Caterina P.; Borojevic, Radovan.

In: British Journal of Haematology, 2016.

Research output: Contribution to journalArticle

Meneses, José Válber L ; Fortuna, Vitor ; de Souza, Eliane Silva ; Daltro, Gildasio Cerqueira ; Meyer, Roberto ; Minniti, Caterina P. ; Borojevic, Radovan. / Autologous stem cell-based therapy for sickle cell leg ulcer : A pilot study. In: British Journal of Haematology. 2016.
@article{ffb76b1ffe0c4ea6ac25c5fb4bc0b4f5,
title = "Autologous stem cell-based therapy for sickle cell leg ulcer: A pilot study",
abstract = "Recurrent chronic leg ulcers are among the most severe vasculopathic complications of sickle cell disease (SCD). Their treatment remains a challenge. Stem cell therapy with bone marrow mononuclear cells (BMMC) is a promising new therapeutic option for other forms of chronic ulcers. This prospective pilot study was performed to evaluate safety and feasibility of BMMC implantation in patients with SCD and chronic leg ulcers (SCLU). Ulcer closure, recurrence and local pain were evaluated. BMMC were successfully administered to 23 SCLU patients and no serious adverse events occurred. During the 6-month follow-up period, 91·3{\%} of patients had improved ulcer pain compared with baseline and 29·2{\%} of the treated ulcers achieved total healing. The frequency of progenitor stem cells (CD34CD45low and fibroblast colony-forming units) in BMMC was found to be significantly reduced in SCLU patients and compared to SCD patients without ulcers (P < 0·004 and P < 0·01, respectively). No relationship was observed between treatment outcome and the number of implanted BM progenitor stem cells. In conclusion, BMMC implantation is a feasible and safe procedure, showing favourable outcomes for the treatment of SCLU, and encouraging further controlled clinical trials.",
keywords = "Bone marrow, Clinical trial, Leg ulcer, Sickle cell disease, Stem cell transplantation",
author = "Meneses, {Jos{\'e} V{\'a}lber L} and Vitor Fortuna and {de Souza}, {Eliane Silva} and Daltro, {Gildasio Cerqueira} and Roberto Meyer and Minniti, {Caterina P.} and Radovan Borojevic",
year = "2016",
doi = "10.1111/bjh.14326",
language = "English (US)",
journal = "British Journal of Haematology",
issn = "0007-1048",
publisher = "Wiley-Blackwell",

}

TY - JOUR

T1 - Autologous stem cell-based therapy for sickle cell leg ulcer

T2 - A pilot study

AU - Meneses, José Válber L

AU - Fortuna, Vitor

AU - de Souza, Eliane Silva

AU - Daltro, Gildasio Cerqueira

AU - Meyer, Roberto

AU - Minniti, Caterina P.

AU - Borojevic, Radovan

PY - 2016

Y1 - 2016

N2 - Recurrent chronic leg ulcers are among the most severe vasculopathic complications of sickle cell disease (SCD). Their treatment remains a challenge. Stem cell therapy with bone marrow mononuclear cells (BMMC) is a promising new therapeutic option for other forms of chronic ulcers. This prospective pilot study was performed to evaluate safety and feasibility of BMMC implantation in patients with SCD and chronic leg ulcers (SCLU). Ulcer closure, recurrence and local pain were evaluated. BMMC were successfully administered to 23 SCLU patients and no serious adverse events occurred. During the 6-month follow-up period, 91·3% of patients had improved ulcer pain compared with baseline and 29·2% of the treated ulcers achieved total healing. The frequency of progenitor stem cells (CD34CD45low and fibroblast colony-forming units) in BMMC was found to be significantly reduced in SCLU patients and compared to SCD patients without ulcers (P < 0·004 and P < 0·01, respectively). No relationship was observed between treatment outcome and the number of implanted BM progenitor stem cells. In conclusion, BMMC implantation is a feasible and safe procedure, showing favourable outcomes for the treatment of SCLU, and encouraging further controlled clinical trials.

AB - Recurrent chronic leg ulcers are among the most severe vasculopathic complications of sickle cell disease (SCD). Their treatment remains a challenge. Stem cell therapy with bone marrow mononuclear cells (BMMC) is a promising new therapeutic option for other forms of chronic ulcers. This prospective pilot study was performed to evaluate safety and feasibility of BMMC implantation in patients with SCD and chronic leg ulcers (SCLU). Ulcer closure, recurrence and local pain were evaluated. BMMC were successfully administered to 23 SCLU patients and no serious adverse events occurred. During the 6-month follow-up period, 91·3% of patients had improved ulcer pain compared with baseline and 29·2% of the treated ulcers achieved total healing. The frequency of progenitor stem cells (CD34CD45low and fibroblast colony-forming units) in BMMC was found to be significantly reduced in SCLU patients and compared to SCD patients without ulcers (P < 0·004 and P < 0·01, respectively). No relationship was observed between treatment outcome and the number of implanted BM progenitor stem cells. In conclusion, BMMC implantation is a feasible and safe procedure, showing favourable outcomes for the treatment of SCLU, and encouraging further controlled clinical trials.

KW - Bone marrow

KW - Clinical trial

KW - Leg ulcer

KW - Sickle cell disease

KW - Stem cell transplantation

UR - http://www.scopus.com/inward/record.url?scp=84987761332&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84987761332&partnerID=8YFLogxK

U2 - 10.1111/bjh.14326

DO - 10.1111/bjh.14326

M3 - Article

JO - British Journal of Haematology

JF - British Journal of Haematology

SN - 0007-1048

ER -